Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy
Open Access
- 9 January 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (1) , e193531
Abstract
Survival outcomes are poor for patients with metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC), with a median survival time of 3 to 5 months without chemotherapy.1,2 Chemotherapy extends median overall survival (OS) by nearly 7 months,2,3 but ultimately the disease becomes refractory to chemotherapy, and all patients experience disease progression after first-line treatment.4-6 Duration of response to second-line treatment is short,4-6 and there are few options for third- and later-line therapy.Keywords
This publication has 41 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatmentWorld Journal of Surgical Oncology, 2013
- Nutritional screening and early treatment of malnutrition in cancer patientsJournal of Cachexia, Sarcopenia and Muscle, 2011
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Alternative pharmacokinetics of S‐1 components, 5‐fluorouracil, dihydrofluorouracil and α‐fluoro‐β‐alanine after oral administration of S‐1 following total gastrectomyCancer Science, 2007
- Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patientsCancer Chemotherapy and Pharmacology, 2007
- Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1Anti-Cancer Drugs, 2006
- Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancerGastric Cancer, 2004
- A Confidence Interval for the Median Survival Time1982